Does CaMKII inhibition reduce atrial fibrillation susceptibility in the setting of insulin resistance?
CaMKII inhibition is identified as a potential therapeutic target to prevent atrial fibrillation in the context of insulin resistance.
IR engenders both atrial structural remodeling and abnormal intracellular calcium homeostasis, contributing to increased AF susceptibility. The inhibition of CaMKII may be a potential therapeutic target for AF in insulin resistance.
Chan et al. (Thu,) studied this question.